Lantern Pharma Inc. (NASDAQ: LTRN) and Oregon Therapeutics are collaborating to advance XCE853, an innovative PDI inhibitor, in various cancer indications. Utilizing Lantern's RADR® AI platform, they aim to uncover biomarkers and efficacy signatures across solid tumors, enhancing precision development. This collaboration, crucial in addressing the complexities of PDI inhibitors, has the potential to revolutionize cancer treatment strategies. PDIs, critical for cancer cell metabolism, are promising targets in cancer therapy, with XCE853 showing efficacy across multiple cancer types.
Oregon Therapeutics' CEO, Marc-Henry PITTY, highlights XCE853's robust preclinical efficacy, indicating its potential across a spectrum of cancers. Led by Oregon project leader, Sandrine Courtès PhD, the collaboration focuses on integrating molecular data to guide patient selection and overcome treatment resistance. With equal IP co-ownership, Lantern Pharma and Oregon Therapeutics aim to unlock novel therapeutic strategies, underscoring the pivotal role of computational tools like RADR® in informing effective cancer treatments. This collaboration marks a significant milestone in oncology research, aiming to address the complexities of cancer drug development and ultimately improve patient outcomes.
No comments yet